Follow Us:

This webcast is co-provided by the CancerNet, LLC and A. Webb Roberts Center for CME of Baylor Scott & White Health.
For more information visit: www.cancernetus.com
![]() |
![]() |
Grantor: Amgen, Inc.; Merck Sharp & Dohme Corp.; AbbVie Inc.; Gilead Sciences Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Celgene; and Takeda/Millennium Pharmaceuticals, Inc.
Release date: July 28, 2017
Valid through: July 28, 2018
Specialty: Hematologists/Oncologists
Topic: Hematological Malignancies
Media: Internet
This webcast is designed to meet the educational needs of hematologists/oncologists and other health care professionals who diagnose, treat, and manage patients with hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia.
This webcast is intended to improve care of patients with hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This program consists of 3 continuing education activites.
Click the links below to review the activity launch pages containing full disclosure information.
Module 2 — Robert Orlowski, MD and Elisabet E. Manasanch, MD — 1.25 AMA PRA Category 1 Credits™
Module 3 — Jorge Cortes, MD and Elias Jabbour, MD — 2.25 AMA PRA Category 1 Credits™